Clinical Trial Detail

NCT ID NCT02456857
Title Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Bevacizumab

Everolimus

Pegylated liposomal-doxorubicin

Age Groups: senior adult

No variant requirements are available.